Abstract
Experiments in animal models suggest that correcting abnormalities in lipid metabolism could help slow the rate of functional decline in patients with chronic progressive renal disease. Circumstantial evidence in humans also suggests that lipids may play a role in the pathogenesis of glomerulosclerosis. Nevertheless, large controlled clinical trials examining the effect of lipid-lowering strategies on renal disease progression have not been carried out. However, the recent development of antilipemic agents that appear to be safe and effective in patients with renal disease should make it possible to determine whether treating hyperlipidemia will reduce the rate of renal disease progression.
| Original language | English (US) |
|---|---|
| Pages (from-to) | 602-608 |
| Number of pages | 7 |
| Journal | Current opinion in nephrology and hypertension |
| Volume | 2 |
| Issue number | 4 |
| DOIs | |
| State | Published - Jul 1993 |